Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF‐κB

Glucocorticoids are an important antiinflammatory treatment of many inflammatory diseases including asthma. However, the mechanisms by which they mediate their suppressive effects are not fully understood. Respiratory epithelial cells are a source of CX3CL1 (fractalkine), which mediates cell adhesion and acts as a chemoattractant for monocytes, T cells, and mast cells. We show, in lung A549 epithelial cells, that the tumor necrosis factor‐α (TNF‐α) and IFNγ synergistically induced protein release and mRNA expression of CX3CL1 is inhibited by dexamethasone, without interfering with cytokine‐induced nuclear translocation of NF‐κB, and by an inhibitor of IκB kinase 2, AS602868. DNA binding assays confirmed the ability of NF‐κB to bind to the proximal CX3CL1 promoter. Chromatin immunoprecipitation assays showed a 5‐fold increase in the recruitment of NF‐κB to the CX3CL1 gene promoter in response to IFNγ/TNF‐α; this too was reversed by dexamethasone. In contrast, dexameth‐asone did not displace NF‐κB from the granulocyte‐macrophage colony‐stimulating factor gene promoter. We conclude that CX3CL1 expression is regulated through the NF‐κB pathway and that dexamethasone inhibits CX3CL1 expression through a glucocorticoid receptor‐dependent (RU486 sensitive) mechanism. This study also provides support for the action of glucocorticoids mediating their suppressive effects on expression by interfering with the binding of transcriptional activators at native gene promoters.— Bhavsar P. K., Sukkar, M. B., Khorasani, N., Lee, K.‐Y., Chung K. F. Glucocorticoid suppression of CX3CL1 (frac‐talkine) by reduced gene promoter recruitment of NF‐kB. FASEB J. 22, 1807–1816 (2008)

[1]  J. Vernejoux,et al.  Fraktalkine Produced by Airway Smooth Muscle Cells Contributes to Mast Cell Recruitment in Asthma1 , 2006, The Journal of Immunology.

[2]  I. Adcock,et al.  Histone deacetylase 2–mediated deacetylation of the glucocorticoid receptor enables NF-κB suppression , 2006, The Journal of experimental medicine.

[3]  J. Cidlowski,et al.  Antiinflammatory action of glucocorticoids--new mechanisms for old drugs. , 2005, The New England journal of medicine.

[4]  P. Barnes,et al.  Validation of IKKβ as therapeutic target in airway inflammatory disease by adenoviral‐mediated delivery of dominant‐negative IKKβ to pulmonary epithelial cells , 2005 .

[5]  K. Chung,et al.  Fractalkine/CX3CL1 production by human airway smooth muscle cells: induction by IFN-γ and TNF-α and regulation by TGF-β and corticosteroids , 2004 .

[6]  H. Garside,et al.  Glucocorticoid Ligands Specify Different Interactions with NF-κB by Allosteric Effects on the Glucocorticoid Receptor DNA Binding Domain* , 2004, Journal of Biological Chemistry.

[7]  Simon C Watkins,et al.  Comprehensive gene expression profiles reveal pathways related to the pathogenesis of chronic obstructive pulmonary disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[9]  S. Durham,et al.  The CX3C chemokine fractalkine in allergic asthma and rhinitis. , 2003, The Journal of allergy and clinical immunology.

[10]  V. Imbert,et al.  AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells , 2003, Oncogene.

[11]  S. McColl,et al.  Inhibition of Cytokine-Induced Fractalkine Production by Bacterial Invasion of Human-Dermal Fibroblasts , 2003, Laboratory Investigation.

[12]  K. Wu,et al.  Inhibition by pentoxifylline of TNF‐α‐stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF‐κB down‐regulation , 2003 .

[13]  J. Saklatvala,et al.  Dexamethasone Causes Sustained Expression of Mitogen-Activated Protein Kinase (MAPK) Phosphatase 1 and Phosphatase-Mediated Inhibition of MAPK p38 , 2002, Molecular and Cellular Biology.

[14]  I. Verma,et al.  NF-κB regulation in the immune system , 2002, Nature Reviews Immunology.

[15]  C. Blobel,et al.  Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). , 2001, The Journal of biological chemistry.

[16]  I. Adcock,et al.  Glucocorticoid-regulated transcription factors. , 2001, Pulmonary pharmacology & therapeutics.

[17]  T. Matsumiya,et al.  Synergistic stimulation, by tumor necrosis factor-α and interferon-γ, of fractalkine expression in human astrocytes , 2001, Neuroscience Letters.

[18]  T. Matsumiya,et al.  Interferon-γ Stimulates the Expression of CX3CL1/Fractalkine in Cultured Human Endothelial Cells , 2000 .

[19]  K. Yamamoto,et al.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. , 2000, Genes & development.

[20]  I. Adcock,et al.  Glucocorticoid Receptor Recruitment of Histone Deacetylase 2 Inhibits Interleukin-1β-Induced Histone H4 Acetylation on Lysines 8 and 12 , 2000, Molecular and Cellular Biology.

[21]  Y. Seo,et al.  Tumour necrosis factor-alpha and interferon-gamma synergistically activate the RANTES promoter through nuclear factor kappaB and interferon regulatory factor 1 (IRF-1) transcription factors. , 2000, The Biochemical journal.

[22]  W. V. Berghe,et al.  Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Menetski.  The Structure of the Nuclear Factor-κB Protein-DNA Complex Varies with DNA-binding Site Sequence* , 2000, The Journal of Biological Chemistry.

[24]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[25]  D. Proud,et al.  Epithelia cells as regulators of airway inflammation. , 1998, The Journal of allergy and clinical immunology.

[26]  I. Adcock,et al.  Effect of dexamethasone on interleukin‐1β‐(IL‐1β)‐induced nuclear factor‐κB (NF‐κB) and κB‐dependent transcription in epithelial cells , 1998 .

[27]  F. Bach,et al.  Glucocorticoid-mediated Repression of NFκB Activity in Endothelial Cells Does Not Involve Induction of IκBα Synthesis* , 1996, The Journal of Biological Chemistry.

[28]  M. F. Shannon,et al.  DNA Triplex Formation Selectively Inhibits Granulocyte-Macrophage Colony-stimulating Factor Gene Expression in Human T Cells* , 1996, The Journal of Biological Chemistry.

[29]  A. Baldwin,et al.  Role of Transcriptional Activation of IκBα in Mediation of Immunosuppression by Glucocorticoids , 1995, Science.

[30]  Joseph A. DiDonato,et al.  Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis , 1995, Science.

[31]  Y. Ohmori,et al.  The interferon-stimulated response element and a kappa B site mediate synergistic induction of murine IP-10 gene transcription by IFN-gamma and TNF-alpha. , 1995, Journal of immunology.

[32]  G. Leikauf,et al.  Corticosteroids increase secretory leukocyte protease inhibitor transcript levels in airway epithelial cells. , 1995, The American journal of physiology.

[33]  A. Jahnke,et al.  Synergistic activation of intercellular adhesion molecule 1 (ICAM‐1) by TNF‐α and IFN‐γ is mediated by p65/p50 and p65/c‐Rel and interferon‐responsive factor Statlα (p91) that can be activated by both IFN‐γ and IFN‐α , 1994 .

[34]  J. Pober,et al.  HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. , 1994, Molecular and cellular biology.

[35]  A. Ray,et al.  Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Darnell,et al.  Synergistic interaction between interferon‐alpha and interferon‐gamma through induced synthesis of one subunit of the transcription factor ISGF3. , 1990, The EMBO journal.

[37]  V. Dixit,et al.  Marked synergism between tumor necrosis factor-alpha and interferon-gamma in regulation of keratinocyte-derived adhesion molecules and chemotactic factors. , 1990, The Journal of clinical investigation.

[38]  I. Verma,et al.  NF-?B regulation in the immune system , 2002 .

[39]  今西 大介.  Identification of a Novel Cytokine Response Element in the Human IFN Regulatory Factor-1 Gene Promoter , 2000 .

[40]  P. Baeuerle,et al.  Function and activation of NF-kappa B in the immune system. , 1994, Annual review of immunology.

[41]  T. Heinzel,et al.  The FASEB Journal • Research Communication Competition between glucocorticoid receptor and NF�B for control of the human FasL promoter , 2022 .

[42]  Y. Seo,et al.  Tumour necrosis factor-α and interferon-γ synergistically activate the RANTES promoter through nuclear factor κ B and interferon regulatory factor 1 ( IRF-1 ) transcription factors , 2022 .